News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Bluebird Bio and Genethon Announce Manufacturing Research Collaboration Centered on Lentiviral Vectors for Gene Therapy


12/14/2010 9:45:19 AM

CAMBRIDGE, Mass. & EVRY, France--(BUSINESS WIRE)--bluebird bio (formerly Genetix Pharmaceuticals Inc.), an emerging leader in the development of innovative gene therapies for severe genetic disorders, and Généthon, a leader in the field of gene therapy treatments for rare diseases, today announced a research collaboration focused on process development and scale up efforts for the manufacturing of lentiviral vectors. This agreement is designed to enable substantial advances in existing manufacturing process for the benefit of both partners. It will also strengthen bluebird bio’s manufacturing platform to enable robust, commercial-scale manufacturing and broaden the company’s capabilities in Europe. Specific terms of the agreement were not disclosed.

Read at BioSpace.com


comments powered by Disqus
Genethon
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES